Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Maxigen Biotech Inc. specializes in the development and manufacturing of advanced medical instruments and supplies, primarily targeting the biopharmaceutical sector in Taiwan and expanding into international markets. The company's competitive edge lies in its proprietary technology for bioprocessing and diagnostics, which enhances the efficiency and accuracy of drug development.
Maxigen generates revenue through the sale of high-margin bioprocessing equipment and diagnostic tools, leveraging its proprietary technology to command premium pricing. The company benefits from strong customer relationships in the biopharmaceutical industry, allowing for recurring revenue through service contracts and upgrades.
Regulatory approvals for new bioprocessing technologies
Expansion into international markets, particularly in North America and Europe
Partnerships with major pharmaceutical companies for product development
Changes in healthcare spending and investment in biotech innovation
Technological disruption from emerging biotechnologies
Regulatory changes impacting product approvals
Increased competition from established biotech firms
Emergence of low-cost alternatives in the medical instruments market
Limited liquidity risks due to low debt levels
Potential for cash flow volatility during market downturns
moderate - The company's performance is somewhat linked to GDP growth as increased healthcare spending typically correlates with economic expansion.
Low - With minimal debt (Debt/Equity of 0.06), rising interest rates have limited impact on financing costs, but could affect overall investment in biotech.
minimal - The company operates with low leverage and does not rely heavily on credit for operations.
growth - Investors are likely attracted to the company's strong revenue growth and high margins.
moderate - The stock has shown some volatility with a 1-year return of -14.2%, indicating sensitivity to market conditions.